Can a platelet booster keep chemo on track for kids with ewing sarcoma?

NCT ID NCT07048249

Recruiting now Symptom relief Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether the drug romiplostim can prevent dangerously low platelet levels caused by chemotherapy in children and young adults with newly diagnosed Ewing sarcoma. About 26 participants will receive romiplostim alongside their standard chemotherapy to see if it helps them avoid treatment delays and platelet transfusions. The goal is to make chemotherapy safer and more manageable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA EWINGS SARCOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Phoenix Children's
RECRUITING

Phoenix, Arizona, 85016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.